Quark Kidney Transplant Drug Receives FDA Orphan Drug Status

The designation allows for possible research and development incentives, and qualifies the company for tax credits and a period of market exclusivity following market approval.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.